PRESS RELEASE

PRESS RELEASE

Jan 25, 2020

News Express! The Clinical Trial of ATG-010 for Peripheral T-cell Lymphoma and NK/T-cell Lymphoma Has Been Approved

Antengene announced today that NMPA has approved the clinical trial application of ATG-010 for relapsed or refractory peripheral T and NK/T-cell lymph...

Jan 17, 2020

Aiming for an IPO, Antengene wants to be China’s Celgene

By Wang Fangqing Chinese biotech start-up Antengene recently hired two former high-profile managers from its funding partner Celgene, now a Bri...

Jan 16, 2020

Antengene Presented a Keynote Speech at J.P. Morgan Conference

San Francisco, U.S. and Shanghai, CHINA, January 15, 2020–Dr. Jay Mei, Chairman & CEO of Antengene Corporation, presented a keynote speech ...

Jan 08, 2020

Former Celgene Chairman and CEO Mark J. Alles Joins Antengene Board of Directors

SHANGHAI, CHINA and PHILADELPHIA, U.S. – – January 8, 2020 – -The Antengene board today announced the appointment of Mr. Mark J. All...

Jan 06, 2020

Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer

SHANGHAI, CHINA and PHILADELPHIA, U.S. — January 6, 2020—Antengene Corporation today announced its appointment of Mr. John Chin, MBA, as Chief...

Jan 03, 2020

News Flash! The PAK4/NAMPT Dual Target Oral Inhibitor, ATG-019, Passed the Review of Investigational New Drug (IND) by Taiwan, China

Shanghai, China — Antengene Corporation announced on January 3, 2020 that the Food and Drug Administration, Ministry of Health and Welfare, Taiwan (...

Nov 06, 2019

Antengene Corporation Announces Exclusive Worldwide License to Develop and Commercialize AZD0364

SHANGHAI, CHINA and LONDON, U.K. — November 6, 2019 – Antengene Corporation today announced that it has entered into a licensing agreement wit...

Oct 18, 2019

Take the crown! — Antengene was awarded the first prize in the 8th China Innovation& Entrepreneurship Competition

Treating Patients Beyond Borders! Scientific and Technological Innovations Make Great Achievements! On Oct 18th, the final of the Eighth China I...

Sep 19, 2019

Latest Progress in the treatment of blood cancer with Selinexor, a selective inhibitor of nuclear export

On September 19, 2019, a conference on the latest academic progress in the treatment of multiple myeloma and diffuse large B-cell lymphoma with AT...

Jul 03, 2019

Karyopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

— XPOVIO is the First and Only Nuclear Export Inhibitor Approved by the FDA — XPOVIO is the First and Only Prescription Medicine Appro...

Jun 22, 2019

Antengene obtaining Korean IND approval for ATG-008, a mTOR Kinase Dual-Targeted Inhibitor

SHANGHAI and SHAOXING, China – On June 22, 2018, Antengene announced that ATG-008, its innovative drug for the treatment of advanced hepatocellu...

Apr 28, 2019

Strong alliance for finding a new treatment of liver cancer: Antengene cooperates with Junshi Biosciences to conduct clinical research on the combination therapy of ATG-008 and Toripalimab to treat a

SHANGHAI, China – On April 28, 2019, Antengene announced a strategic partnership with Junshi Biosciences (1877. HK, 833330.OC) to conduct a clin...

Apr 08, 2019

Antengene Corporation Announces Establishment of U.S. Subsidiary and Collaboration with the Baruch S. Blumberg Institute

SHANGHAI, China and PHILADELPHIA, Pennsylvania – April 8, 2019 – Antengene Corporation, a clinical and commercial stage biopharmaceutical company ...

Feb 13, 2019

Antengene Team Standing Out as a Leader in Innovation and Entrepreneurship

SHANGHAI and SHAOXING, China, Feb 13, 2019—Recently, the Science and Technology Department of Zhejiang Province announced the list of “2018 le...

Jan 29, 2019

ATG-010, China’s first Selective Inhibitor of Nuclear Export obtains IND approval for the treatment of multiple myeloma

SHANGHAI, China – Antengene announced recently that ATG-010, a new Category I drug developed by the company to treat patients with relapsed and/...

Jan 02, 2019

Antengene Corporation Raises $120 Million in Series B Financing

SHANGHAI and SHAOXING, China, Jan. 2, 2019 — Antengene Corporation (Antengene), a clinical stage therapeutics company focused on oncology, annou...

Dec 05, 2018

Antengene Corporation won the Project Support of “the 13th Five- Year National Major New Drug Development Project”

SHAOXING and SHANGHAI, China, Dec 5, 2018 (Antengene) —Rencently, the Development Center for Medical Science & Technology of National Health an...

Sep 22, 2018

Antengene publishes clinical data on ATG-010 (Selinexor) for the treatment of refractory and/or relapsed multiple myeloma and relapsed diffuse large B-cell lymphoma at the Annual Meeting of Chinese S

On September 22, 2018, at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) held in Xiamen, China, Antengene published the cl...

Sep 21, 2018

Antengene Presents a Series of Reports on TORC1/TORC2 Dual-Targeted Inhibitor ATG-008 at the 21st Annual Meeting of Chinese Society of Clinical Oncology

On September 21, 2018 (Beijing time), Antengene Corporation presented a special report entitled “Novel TORC1/2 Inhibitor for Treatment of Hepatocell...

Aug 07, 2018

Antengene launches patient enrollment for TORC1/2 dual-targeted inhibitor ATG-008 in Taiwan

SHANGHAI, China, August 7, 2018 – Antengene Corporation announced that it has officially launched patient enrollment of ATG-008 in Taiwan and South ...

Aug 07, 2018

Karyopharm,Antengene Corporation’s Strategic Partner, Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor (ATG-010)as a Treatment for Patients w

NEWTON, Mass. and SHANGHAI, China – Aug 7, 2018 – Antengene Corporation’s Strategic Partner Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinic...

Jul 21, 2018

Antengene and WuXi STA announced a strategic cooperation in process R&D and manufacturing

SHANGHAI, China, July 21, 2018 – Antengene and WuXi STA, a subsidiary of WuXi AppTech, which is a global leader of Contract Development and Manu...

Jul 20, 2018

Antengene Corporation’s Strategic Partner, Karyopharm Therapeutics, Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients

Shanghai, China and NEWTON, Mass. – July 18, 2018 – Antengene Corporation’s Strategic Partner, Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a cli...

Jun 13, 2018

ATG-008, China’s first TORC1/2 dual-targeted inhibitor of the new generation, has obtained IND approval

On June 13, 2018, Antengene Corporation announced that ATG-008, a new Category I drug developed by the company for the treatment of advanced hepatocel...

May 26, 2018

International Torch Study (ATG-008-HCC-001) Investigator Meeting held by Antengene

On May 25-26, 2018, Torch Study (ATG-008-HCC-001) Investigator Meeting and Launch Ceremony of Its Clinical Trial was held on the shore of the beautifu...

May 24, 2018

Antengene and Karyopharm Sign Exclusive License Agreement to Develop and Commercialize Selinexor, Eltanexor, Verdinexor and KPT-9274 in China and Other Regions in Asia

SHANGHAI, China and NEWTON, Mass. – May 24, 2018 – Antengene Corporation (Antengene) and Karyopharm Therapeutics Inc. (Nasdaq:KPTI) (Karyopharm), ...

May 15, 2018

Dr. Yijun Yang and Dr. Bo Shan joined Antengene Corporation

Antengene Co., Ltd. announced on May 15, 2018 that Dr. Yijun Yang and Dr. Bo Shan joined Antengene as Vice President. Dr. Yijun will be responsible fo...

Mar 26, 2018

Antengene Corporation Announces TFDA Approval of IND Application for a Phase II Study of ATG-008, a Next Generation mTOR Inhibitor, in Patients with Late-stage Hepatocellular Carcinoma (HCC)

On March 26, 2018, Antengene Corporation, a China-based biopharmaceutical company that focuses on introducing cutting-edge treatments to China and oth...

Feb 11, 2018

Antengene Corporation has submitted The Phase 2 Clinical Trial Application of ATG-008 to China, Taiwan and Korea

BEIJING, CHINA, February 7,–Antengene Corporation has submitted The Phase 2 Clinical Trial Application of ATG-008 to China, Taiwan and Korea. ...

Nov 30, 2017

Antengene Corporation attended Drug Development Case Study Workshop held by CFDA

BEIJING, CHINA, November 30, 2017–Dr. Jay Mei, founder of Antengene Corporation attended Drug Development Case Study Workshop with the CFDA in B...